PKD1 Truncating Mutations Accelerate eGFR Decline in Autosomal Dominant Polycystic Kidney Disease Patients

Abstract

<b><i>Introduction:</i></b> Autosomal dominant polycystic kidney disease (ADPKD) is a monogenic disease characterized by the accumulation of fluid-filled cysts in the kidneys, leading to renal volume enlargement and progressive kidney function impairment. Disease severity, though, may vary due to allelic and genetic heterogeneity. This study aimed to determine genotype-phenotype correlations between <i>PKD1</i> truncating and non-truncating mutations and kidney function decline in ADPKD patients. <b><i>Methods:</i></b> We established a single-center retrospective cohort study in Kuwait where we followed every patient with a confirmed <i>PKD1</i>-ADPKD diagnosis clinically and genetically. Renal function tests were performed annually. We fitted generalized additive mixed effects models with random intercepts for each individual to analyze repeated measures of kidney function across mutation type. We then calculated survival time to kidney failure in a cox proportional hazards model. Models were adjusted for sex, age at visit, and birth year. <b><i>Results:</i></b> The study included 22 truncating and 20 non-truncating (42 total) patients followed for an average of 6.6 years (range: 1–12 years). Those with <i>PKD1</i> truncating mutations had a more rapid rate of eGFR decline (−4.7 mL/min/1.73 m² per year; 95% CI: −5.0, −4.4) compared to patients with <i>PKD1</i> non-truncating mutations (−3.5 mL/min/1.73 m² per year; 95% CI: −4.0, −3.1) (<i>p</i> for interaction &lt;0.001). Kaplan-Meier survival analysis of time to kidney failure showed that patients with <i>PKD1</i> truncating mutations had a shorter renal survival time (median 51 years) compared to those with non-truncating mutations (median 56 years) (P for log-rank = 0.008). <b><i>Conclusion:</i></b> In longitudinal and survival analyses, patients with <i>PKD1</i> truncating mutations showed a faster decline in kidney function compared to patients <i>PKD1</i> non-truncating mutations. Early identification of patients with <i>PKD1</i> truncating mutations can, at best, inform early clinical interventions or, at least, help suggest aggressive monitoring.